文献速递白血病

奥英妥珠单抗治疗成人急性淋巴细胞白血病中细胞遗传学的预后意义

Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin.
PubMed 文献 · Am J Hematol · 2019-01-17

该研究为Ⅲ期开放标签随机INO-VATE试验的事后探索性分析,评估基线细胞遗传学与奥英妥珠单抗(InO)治疗复发/难治性急性淋巴细胞白血病(R/R ALL)患者结局的关系。326例随机患者中284例有筛查核型数据(InO组144例,标准治疗组140例)。InO组内各细胞遗传学亚组的完全缓解/完全缓解伴血液学不完全恢复(CR/CRi)、微小残留病阴性率和总生存(OS)无显著差异;在二倍体≥20个中期分裂相、复杂核型和「其他」亚组中,CR/CRi率和OS风险比均 favor InO 优于标准治疗。

要点

  • InO组内各细胞遗传学亚组的CR/CRi、MRD阴性率和OS无显著差异。
  • 二倍体≥20个中期分裂相、复杂核型和「其他」亚组中CR/CRi率 favor InO 优于标准治疗。
  • 上述三个亚组中OS风险比 favor InO 优于标准治疗。

核心结论

  • 总体而言,InO对具有特定基线核型的R/R ALL患者有效并提供实质性临床获益。

研究设计与样本

  • Ⅲ期、开放标签、随机INO-VATE试验的事后探索性分析,数据截止2016年3月8日。
  • 326例随机患者中284例有筛查核型数据(InO组144例,标准治疗组140例)。

主要发现

  • InO组内各细胞遗传学亚组间CR/CRi率、MRD阴性率和OS无显著差异。
  • 在二倍体≥20个中期分裂相、复杂核型和「其他」细胞遗传学亚组中,CR/CRi率 favor InO 优于标准治疗。
  • 在二倍体≥20个中期分裂相、复杂核型和「其他」细胞遗传学亚组中,OS风险比 favor InO 优于标准治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Karyotype is frequently used to predict response and outcome in leukemia. This post hoc exploratory analysis evaluated the relationship between baseline cytogenetics and outcome in patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) treated with inotuzumab ozogamicin (InO), a humanized CD22 antibody conjugated to calicheamicin, in the phase 3, open-label, randomized INO-VATE trial. Data as of March 8, 2016, are presented in this analysis. Of the 326 patients randomized, 284 had screening karyotyping data (144 in the InO arm and 140 in the standard care [SC] arm). With InO, complete remission or complete remission with incomplete hematologic recovery (CR/CRi), minimal residual disease negativity rates, and overall survival (OS) were not significantly different between cytogenetic subgroups. CR/CRi rates favored InO over SC in the diploid with ≥20 metaphases, complex, and "other" cytogenetic subgroups. The OS hazard ratio favored InO over SC in the diploid with ≥20 metaphases, complex, and other cytogenetic subgroups. Generally, InO is effective and provides substantial clinical benefit in patients with R/R ALL who have specific baseline karyotypes.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Jabbour E, Advani AS, Stelljes M, et al. Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. Am J Hematol. 2019. PMID: 30623490. doi:10.1002/ajh.25394

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。